Table 4.
Effect of sex, age and period of diagnosis on mortality risk in the subgroups of metabolic diseases
| Sex | Age at diagnosis | Period of diagnosis | ||||
|---|---|---|---|---|---|---|
| HRb | 95% CI | HRc | 95% CI | HRd | 95% CI | |
| Metabolic diseases | ||||||
| Disorders of mitochondrial metabolism | 3.12 | 0.99–9.80 | 1.05 | 1.02–1.09 | 0.67 | 0.20–2.25 |
| Lysosomal storage diseases | 1.21 | 0.56–2.61 | 0.99 | 0.96–1.01 | 1.04 | 0.39–2.79 |
| Disorders of vitamin and non-protein cofactor absorption and transport | 5.87 | 0.96–35.98 | 1.05 | 1.00–1.11 | 0.17 | 0.02–1.54 |
| Disorders of metal metabolism and transport | 3.14 | 0.96–10.30 | 1.09 | 1.03–1.15 | 0.87 | 0.31–2.43 |
| Disorders of protein metabolism and transport | 0.72 | 0.049–1.04 | 1.05 | 1.04–1.07 | 0.96 | 0.61–1.50 |
| Other metabolic diseasesa | 2.04 | 0.81–1.17 | 1.04 | 1.03–1.07 | 0.70 | 0.26–0.94 |
aGroup of metabolic diseases not attributable to the others listed in the table. Females were the reference group in the analysis by sex; the 2000–2009 period was the reference group and was compared to 2010–2018 period. HR hazard ratio; 95% CI 95% confidence interval
bHRs were adjusted for age and period of diagnosis
cHRs were adjusted for sex and period of diagnosis
dHRs were adjusted for sex and age at diagnosis. Statistically significant differences are reported in bold